Disparities and trends in viral suppression during a transition to a "test and treat" approach to the HIV epidemic, San Francisco, 2008-2012

Journal of Acquired Immune Deficiency Syndromes

Volumn 70, Issue 5, 2015, Pages 529-537

  Schwarcz, Sandra ^a,b   Hsu, Ling Chin ^a   Scheer, Susan ^a  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

HIV; HIV testing; HIV treatment; Test and treat; Viral suppression

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ANTIVIRAL THERAPY; ASIAN; CAUCASIAN; CD4 LYMPHOCYTE COUNT; CONFERENCE PAPER; EPIDEMIC; FEMALE; HEALTH DISPARITY; HETEROSEXUALITY; HIV TEST; HOMELESSNESS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MEDICALLY UNINSURED; MEN WHO HAVE SEX WITH MEN; MIDDLE AGED; MISCELLANEOUS NAMED GROUPS; PERSONS WHO INJECT DRUG; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; RESIDENTIAL AREA; RESIDENTS OF A NONIMPOVERISHED NEIGHBORHOOD; TEST AND TREAT STRATEGY; TIME TO TREATMENT; VIRAL LOAD TESTING; YOUNG ADULT; CALIFORNIA; HEALTH SURVEY; HIV INFECTIONS; RISK FACTOR; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; RISK FACTORS; SAN FRANCISCO; VIRAL LOAD; YOUNG ADULT;

EID: 84947707982     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000794     Document Type: Conference Paper

References (41)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;280:1497-14503.
2. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 1997;277:112-116.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolecents. Department of Health and Human Services; 2007. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL000721. pdf. Accessed June 12, 2014.
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1 Infected Adults and Adolecents. Department of Health and Human Services; 2009. Available at: http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL001561. pdf. Accessed June 12, 2014.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services; 2012. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl. pdf. Accessed June 12, 2014.
7. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375:2092-2098.
8. Quinn TA, Wawer MA, Sewankambo N, et al. Viral load and sexual transmission of human immunodeficiency virus type-1. N Engl J Med. 2000;342:921-929.
9. Diffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301:2380-2382.
10. Montaner JSG, Hogg R, Wood E, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368:531-536.
11. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
12. Hsu LC, Truong HM, Vittinghoff E, et al. Trends in early initiation of antiretroviral therapy and characteristics of persons with HIV initiating therapy in San Francisco, 2007-2011. JInfect Dis. 2014;209:1310-1314.
13. Fleishman JA, Yehia BR, Moore RD, et al. Disparities in receipt of antiretroviral therapy among HIV-infected adults (2002-2008). Med Care. 2012;50:419-427.
14. Writing Committee for the HIV CAUSAL Collaboration. When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med. 2011;154:509-515.
15. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. NEngl J Med. 2009; 360:1815-1826.
16. San Francisco Department of Public Health. HIV/AIDS Epidemiology Annual Report 2011. San Francisco, CA; San Francisco Department of Public Health; 2012.
17. Jain V, Deeks SG When to start antiretroviral therapy. Curr HIV/AIDS Rep. 2010;7:60-68.
18. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLos Med. 2008;5:e203.
19. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
20. Russell R. City endorses new policy for treatment of HIV. The New York Times. 2010. Available at http://www.nytimes.com/2010/04/04/us/04sftreatment.html. Accessed March 5, 2014.
21. 2010 San Francisco Department of Public Health. HIV Prevention Plan. Available at: http://www.sfhiv.org/wp-content/uploads/HIV-Prev-Plan2010- final.pdf Accessed May 4, 2015.
22. Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by "test and treat" in hyper-endemic settings. AIDS. 2010;24: 729-735.
23. Eaton JW, Johnson LF, Salomon JA, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PLoS Med. 2012;9:e1001245.
24. Cohen SM, Wan Handel MM, Branson BM, et al. Vital signs: HIV prevention through care and treatment-United States. MMWR Morb Mortal Wkly Rep. 2011;60:1618-1620.
25. Laffoon B, Johnson AD, Cohen S, et al. National Black HIV/AIDS awareness. Disparities in diagnosis of HIV infection between blacks/African Americans and other racial/ethnic populations-37 states, 2005-2008. MMWR Morb Mortal Wkly Rep. 2011;60:1999-2002.
26. Muthulingam D, Chin J, Hsu L, et al. Disparities in engagement in care and viral suppression among persons with HIV. J Acquir Immune Defic Syndr. 2013;63:112-119.
27. Kassanjee R, Pilcher C, Keating S, et al. Independent evaluation of predicable incidence assays for HIV surveillance. Paper presented at: Poster session P-W6: Conference on Retroviruses and Opportunistic Illnesses. Abstract no. 1005; March 3-6, 2014; Boston, MA.
28. U.S. Census Bureau. 2006-2010 American Community Survey; 2010. Available at: www.census.gov/programs-surveys/acs/data.htm.
29. San Francisco Department of Public Health. HIV/AIDS Epidemiology Annual Report 2013. San Francisco, CA; San Francisco Department of Public Health; 2014.
30. Buskin SE, Kent JB, Dombrowski JC, et al. Migration distorts surveillance estimates of engagement in care: results of public health investigations of persons who appear to be out of HIV care. Sex Transm Dis. 2014;41:35-40.
31. Zhou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol. 2004;159:702-706.
32. Torian LV, Xia Q. Achievement and maintenance of viral suppression in persons newly diagnosed with HIV. New York City, 2006-2009: using surveillance data to measure the treatment part of "test and treat". J Acquir Immune Defic Syndr. 2013;63:379-386.
33. Xia Q, Kersanske LS, Wiewel EW, et al. Proportions of patients with HIV retained in care and virally suppressed in New York City and the United States: higher than we thought. J Acquir Immune Defic Syndr. 2012;68:351-357.
34. Dombroski JC, Kent JB, Buskin SE, et al. Population based metrics for the timing of HIV diagnosis, engagement in HIV care, and virologic suppression. AIDS. 2012;26:77-86.
35. Buchbinder S. "Getting to zero" in San Francisco: zero HIV infections, zero HIV deaths, zero HIV stigma. Available at: https://www.sfdph.org/dph/files/sfchip/GettingToZero-HIV.pdf Accessed May 18, 2015.
36. Mugavero MJ, Amico KR, Westfall AO, et al. Early retention in HIV care and viral load suppression: implications for a test and treat approach to HIV prevention. J Acquir Immune Defic Syndr. 2012;59: 86-93.
37. Hall HI, Gray KM, Tang T, et al. Retention in care of adults and adolescents living with HIV in 13 U.S. areas. J Acquir Immune Defic Syndr. 2012;60:77-82.
38. Hanna DB, Buchacz K, Gebo KA, et al. Trends and disparities in antiretroviral therapy initiation and virologic suppression among newly treatment-eligible HIV-infected individuals in North America, 2001-2009. Clin Infect Dis. 2013;56:1174-1182.
39. Chander C, Himelhoch S, Fleishman JA, et al. HAART receipt and viral suppression among HIV-infected patients with co-occurring mental illness and illicit drug use. AIDS Care. 2009;21:655-663.
40. Kalichman SC, Grebler BA. Stress and poverty predictors of treatment adherence among people with low-literacy living with HIV/AIDS. Psychosom Med. 2010;72:810-816.
41. Ribaudo HJ, Smith KY, Robbins GK, et al. Racial differences in response to antiretroviral therapy for HIV infection: an AIDS Clinical Trials Group (ACTG) study analysis. Clin Infect Dis. 2013;57:1607-1617.